Studies from the past decade have shed light on the important contributions of the gut microbiota to key aspects of our health. Although the gut microbiota prov ides substantial benefit to the host, in particular with respect to metabolism and immunity 1,2 , there is also increasing recognition of the involvement of the gut microbiota in disease processes 3 . In addition to bac teria, the gut microbiota contains Archaea, eukaryotes such as fungi, and viruses. As the role of the commen sal nonbacterial gut microbiota is poorly understood, we will exclusively focus on the bacterial gut micro biota in this Review. The bacterial gut microbiota promotes disease development not only via local effects, as in chronic IBD 4, 5 , but also at distant sites such as the liver, heart, brain and the haematopoietic system [6] [7] [8] [9] [10] . Likewise, there is accumulating evidence for an important contrib ution of the gut microbiota to carcino genesis via local and longdistance effects 11 . Owing to its anatomical connection via the portal vein, the liver is closely linked to the gut. Not only does the liver receive nutrientrich blood from the intestine, but it is also the first target of the intestinal microbiota, microbe associated molecu lar patterns (MAMPs) -which can elicit inflam matory responses via patternrecognition receptors (PRRs) -and microbial metabolites. The multilayer intestinal barrier ensures that hepatic exposure to pro inflammatory MAMPs is minimal. However, a failing gut barrier and alterations of the gut micro biota in chronic liver disease (CLD) contribute to chronic inflammation and the progression of liver diseases 12 , and thereby increase risk of the development of hepato cellular carci noma (HCC) as the final stage of the disease process [13] [14] [15] . Here, we will review how the gut microbiota promotes the development of HCC, focusing on alter ations of the gut microbiota at different disease stages and mech anisms by which it contributes to disease progression and HCC development in different types of liver dis eases. We will then review therapeutic opportunities to interrupt this diseasepromoting signalling axis, with a focus on the most promising drugs and clinical settings to test these therapeutic strategies.
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Here, we will review how the gut microbiota promotes the development of HCC, focusing on alter ations of the gut microbiota at different disease stages and mech anisms by which it contributes to disease progression and HCC development in different types of liver dis eases. We will then review therapeutic opportunities to interrupt this diseasepromoting signalling axis, with a focus on the most promising drugs and clinical settings to test these therapeutic strategies.
The intestinal epithelial barrier Strict separation of microbial entities from the host compartment forms the basis of a symbiotic relation ship between host and microbiota. In the intestine, this partitioning is achieved by a wellmaintained, multilayer barrier 16, 17 . This barrier relies on an intact epithelial lining, a mucus layer, Paneth and goblet cells, mucosa associated lymphoid tissue, as well as a number of secreted factors such as IgA and defensins 17 . With constant changes in intestinal luminal contents and high epithelial cell turnover, the gut barrier is a highly dynamic system and can rapidly adjust. Continuous sampling of gut microorganisms by specialized epithelial cells, termed M cells, regulates the microbiota through the secretion of antibacterial peptides by Paneth cells; vice versa, the intestinal barrier and epithelial cell growth 1 are regulated by the microbiota 17 . Moreover, the intes tinal microbiota also suppresses the growth of patho bionts, as demonstrated by the protective role of the commensal microbiota against Clostridium difficile infection 18 and the increased susceptibility of germfree mice to infection with pathogens 19 . Bile acids represent another key factor in this complex system, regulating epithelial barrier function and the proliferation of intes tinal epithelial cells via farnesoid Xactivated receptor (FXR)dependent and epidermal growth factor recep tor (EGFR)dependent pathways [20] [21] [22] , and controlling the growth and adhesion of intestinal bacteria 16 . Notably, bile acids provide an important link between the liver, bac terial microbiota and the intestine. After being synthe sized in the liver, bile acids are metabolized by bac teria and sensed by FXR expressed by intestinal epithelial cells (IECs), which in turn provide feedback to the liver via the FGF19 (known as FGF15 in mice) pathway 23 . Acute and chronic liver diseases exert major effects on the composition of the intestinal microbiota and intesti nal barrier function, resulting in dysbiosis and a leaky gut, respectively. The majority of studies on the gut-liver axis in CLD have focused on lipopolysaccharide (LPS), a cell wall component of Gramnegative bacteria and one of the most potent inducers of inflammation via bind ing to the transmembrane receptor Tolllike receptor (TLR)4 (discussed in detail later). Mean portal vein LPS levels increase in chronic liver injury from <3 pg/ml in healthy volunteers to 4.9 pg/ml, 7.9 pg/ml and 10.2 pg/ml in patients with Child-Turcotte-Pugh (CTP) cirrhosis stage A, B and C, respectively 24 . Likewise, chronic alcohol intake increases endotoxin levels in peripheral blood from 2.5 pg/ml in healthy individuals to 14-19 pg/ml in patients with alcoholic liver disease (ALD) 25 . Increases in blood LPS levels reflect gut leakiness and are mirrored by a number of other alterations such as increased intesti nal permeability to highmolecularweight polyethylene glycol in patients with ALD 26 and to fluorescein isothio cyanate (FITC)-dextran in mouse models of alcoholic and biliary liver disease 27, 28 . Moreover, there is an increase in levels of bacterial DNA, a wellestablished TLR9 ago nist, in the peripheral blood of patients with CLD 29 . Together, these findings demonstrate that the chronically injured liver is subject to increased exposure to a wide range of TLR ligands as well as other bacterial products and metabolites. These proinflammatory mediators not only promote the development of CLD but also set the stage for the development of HCC [13] [14] [15] .
Mechanisms underlying the failure of the intes tinal barrier and development of a leaky gut are not fully understood and are most likely multifactorial. Contributing factors include decreased bile acid secre tion, bacterial dysbiosis and a subsequent increase in the expression of inflammatory cytokines in the intes tine, a failing immune system and increased perme ability of the gut-vascular barrier 16, 30, 31 . Although the development of a leaky gut has been demonstrated by a wide body of literature, the changes in the intestinal microbiota in patients with CLD are only beginning to be understood. Studies in the past few years have demonstrated profound alter ations of the intestinal microbiota in patients with cirrhosis, showing increased abundance of Enterobacteriaceae as well as strains that are typically found in the oral micro biota, such as Veillonellaceae and Streptococcaceae, consistent with an invasion of microorganisms from the mouth to the gut in liver cirrhosis 32, 33 . At the same time, there is decreased abundance of beneficial bac teria in the gut, such as Lachnospiraceae 33 . These changes seem to develop progressively, as cirrho sis stage is corre lated positively with abundance of Enterobacteriaceae and neg atively with Lachnospiraceae abundance 33, 34 . Likewise, a number of studies have demonstrated alter ations of the gut microbiota in earlier stages of liver dis ease 35, 36 and in animal models 16, 31 . However, the current understanding of the alterations of the gut microbiota in patients with liver diseases remains incomplete and is complicated by several factors: changes in the gut microbiota might be diseasespecific; patients with advanced liver disease often take drugs that alter the composition of the microbiota, such as anti biotics, lactulose or antacids; the faecal microbiota might not reflect some of the most character istic alterations in CLD, such as bacterial overgrowth in the upper gastro intestinal tract; and there could be changes in the adher ent micro biota that are not reflected by studying luminal microbiota. In addition, welldesigned functional stud ies are needed to understand the contribution of dys biosis to liver disease. Not only is it essential to confirm that dysbiosis is a driver of liver disease development and progression, but it is also important to determine whether dysbiosis contributes to gut leakiness in CLD.
Gut microbiota and disease progression HCC is typically the result of chronic disease processes in the liver and almost never occurs spontaneously in the absence of liver disease. Moreover, ~80-90% of HCCs occur in advanced fibrotic or cirrhotic livers, which translates to around one in three patients with compen sated liver cirrhosis developing HCC in their lifetimes 37, 38 . Hence, the presence of liver cirrhosis represents the most important unifying risk factor for the development of HCC. However, additional factors are involved and each type of underlying liver disease entails a specific risk for the development of HCC in cirrhosis; diseases such as chronic hepatitis B and C or haemochromatosis entail a relatively high risk compared with the relatively low risk of HCC for diseases such as autoimmune hepatitis or ALD [38] [39] [40] . To dissect the contribution of the failing gut
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• Intestinal dysbiosis and increased bacterial translocation contribute to the pathophysiology of chronic liver disease (CLD) and hepatocarcinogenesis • A large body of literature has demonstrated that targeting the gut-microbiota-liver axis can inhibit the development of hepatocellular carcinoma (HCC) in mice and rats • Promising findings from these preclinical studies in mice and rats have not yet been translated to clinical settings, presenting therapeutic opportunities • Targeting the gut-liver axis by nonabsorbable antibiotics such as rifaximin might not only prevent the development of HCC in patients with CLD, but additionally reduce other complications and improve survival barrier and alterations of the gut microbiota to HCC development, it is not only important to understand how they might affect the development of HCC within a cirrho tic liver but also how these factors drive the pro gression of liver disease to advanced disease stages (which entail a statistically significant risk of HCC development). Herein, we will summarize diseasespecific mechanisms by which the gut microbiota promotes progression of liver disease.
ALD. ALD contributes to about half of all cirrhosis cases 41 and is a cofactor in liver disease induced by HBV, HCV and NASH. Although ALD might have a lower relative risk of causing HCC than other types of CLD 39 , the sheer number of patients with alcoholic cirrhosis means that the absolute number of HCCs caused by ALD is high. Moreover, subgroups of patients, such as those with cirrhosis, men, patients >55 years, individ uals positive for antibodies against hepatitis B core protein (antiHBc) as well as patients with high cumulative con sumption of alcohol, might have extremely highrisk of HCC development (>40% in a 10year period for some patients) 42 . The key contribution of the gut microbiota to early stages of ALD has been firmly established in the past two decades. Even a single binge of alcohol is sufficient to increase bacterial translocation, as evidenced by an increase of LPS in portal blood in rats from undetect able levels to 30-80 pg/ml after ethanol administration 16 . Likewise, serum LPS levels are increased in patients with chronic alcohol abuse 16 . The ability of ethanol and its metabolite acetaldehyde to disrupt tight junctions con tributes to the high levels of bacterial translocation in ALD 43 . Moreover, mice receiving intragastric alcohol feeding show perturbations of the intestinal micro biota, with reduced synthesis of longchain fatty acids 44 . A number of functional studies have shown a key contrib ution of the gutmicrobiota-TLR4 axis to ALD 45 : global TLR4 deficiency in mice as well as gut sterilization with nonabsorbable antibiotics in rats reduces hepatic steatosis, oxidative stress and inflammation [46] [47] [48] . Owing to difficulties in modelling advanced stages of ALD in rodents, the functional contribution of the intestinalmicrobiota-TLR4 axis in advanced liver dis ease, such as in the development of cirrhosis and HCC, is not well known. In one study, ethanolfed transgenic mice with global TLR4 deficiency, which additionally expressed the NS5A HCV protein, were protected from HCC development, suggesting that TLR4 signalling synergizes with HCV to promote HCC 49 . This finding fits well with the wellestablished clinical observation that alcohol abuse is an important cofactor in promot ing liver disease development and HCC in patients with chronic HCV infection 50 and suggests a potential role for the LPS-TLR4 axis in the synergy between alcohol and HCV.
NAFLD.
Although recognized as a disease only about two decades ago, NAFLD represents the most prevalent liver disease globally, and is projected to become the lead ing contributor to CLD and the development of HCC 51 .
In comparison to other CLDs, NAFLD carries a low rela tive individual risk of HCC development, but makes a large populationwide contribution to HCC develop ment owing to its high prevalence 51 . Studies in germfree and gnotobiotic mice have revealed a key contrib ution of the gut microbiota to metabolism and energy harvest. As such, germfree mice display decreased body weight despite increased food intake 52 . Metagenomic and microbiota transplantation studies have shown that the gut microbiota from individuals who are obese is more efficient at energy extraction and thereby contributes to obesity 53, 54 . Hence, treatment with antibiotics amelior ates highfatdiet (HFD)induced NAFLD in mice 55 . Moreover, patients with NAFLD display dys biosis; how ever, bacterial abundance patterns were not consistent between studies, with levels of Bacteroidetes increased in some studies 36, 56 and decreased in other studies 57, 58 , and a substantial overlap with healthy individ uals 59 . Interestingly, dys biotic microbiota from mice fed a HFD metabolize and convert dietary choline into methyl amines, resulting in low circulating levels of plasma phosphatidylcholine 60 . These low levels of phosphatidyl choline impaired secretion of VLDL, thereby redu cing hepatic lipid export and contrib uting to fatty liver 61 . Thus, alterations in choline metabolism might link dysbiosis to the development of NAFLD.
The contribution of the gut microbiota to NASH, a progressive form of NAFLD, is not as well documented as its role in earlier disease stages. HFD increases intesti nal permeability in mice with a twotothreefold increase in systemic LPS levels 62 . Likewise, intestinal perme ability (measured by urinary excretion of 51 Crethylene diamine tetraacetate) is increased in patients with NAFLD 63 . In a model of NASH induced by highfat and high cholesterol diet given to ApoEdeficient mice, TLR4 deficiency reduced hepatic inflammation and injury 64 . In the methionine-cholinedeficient (MCD) diet model, the microbiota has a key role in NASH exacerbation, as demonstrated by experiments finding that cohousing transmitted NASH risk and antibiotics reduced NASH risk 65 . Conversely, faecal microbiota transplantation from healthy mice attenuated steato hepatitis in HFD treated mice 66 . The gut microbiota also has an impor tant role in promoting HCC development in a mouse model in which HCC is driven by the carcinogen 7,12dimethylbenz(a)anthracene (DMBA) and subse quent HFD 15 . However, this model does not incorporate key features of NASH, such as liver fibrosis and insulin resistance. Hence, further studies are needed to deter mine the functional role of dysbiosis in the progression of NASH and HCC in mouse models that incorporate adiposity and insulin resistance.
Chronic viral hepatitis.
In contrast to ALD and NAFLD, there is little information on the role of the gut micro biota in chronic viral hepatitis. Current data suggest that dysbiosis and alterations of the gut-liver axis in patients with endstage viral hepatitis and cirrhosis are similar to alterations in patients with cirrhosis from other causes 67 . However, it is not known whether the gut microbiota contributes to the pathophysiology of chronic viral hepatitis and its progression to more advanced stages. A study published in 2015 demonstrated that the gut microbiota controls immune responses and tolerance to HBV in adult mice, with 6 weeks of antibiotic treatment preventing the clearance of HBV 68 . Whether the impaired response to HBV is mediated by specific bacteria or the result of broad suppression of the bacterial microbiota remains an important unanswered question. Notably, HBV titres in patients positively corre late with risk of dis ease progression and HCC development 69 . Hence, the gut micro biota might control antiviral responses that affect disease progression and HCC development.
Liver fibrosis. Liver fibrosis is part of the hepatic wound healing response and common to all types of advanced CLD. Notably, there is a strong correlation between hepatic fibrosis and HCC development with 80-90% of HCCs developing in fibrotic or cirrhotic livers. Thus, fibrosis represents a risk factor for HCC development 70 . Strong evidence supports an important contribution of the microbiota-TLR4 axis to liver fibrosis. Studies from the past six decades have shown that antibiotics prevent hepatic injury and fibrosis induced by carbon tetrachloride (CCl 4 ) treatment, bile duct ligation or a choline deficient diet, and that endotoxin enhances hepatic fibrosis induced by a cholinedeficient diet [71] [72] [73] . Studies in knockout mice have highlighted a key role for TLR4 and other important mediators in the TLR4 sig nalling pathway, such as CD14 and lipopolysaccharide binding protein (LBP), in experimental models of toxic and cholestatic liver fibrosis 73, 74 . However, studies published in the past few years have demonstrated an increase in liver fibrosis in germfree mice 75, 76 , which seemingly contradicts the decrease of liver fibrosis seen in gut sterilized mice. It has become apparent that the endogen ous commensal microbiota provides hepato protective signals and that complete absence of the gut microbiota results in increased liver injury -probably owing to an absence of TLR4mediated activation of antiapoptotic NFκB signalling -and a subsequent increase in extent of liver fibrosis, as demonstrated in several models 13, 75, 76 . Nonetheless, the bacterial micro biota has an important role in promoting HCC in the setting of liver fibrosis, as demonstrated by reduced HCC formation in TLR4deficient, germfree and antibiotic treated mice in a diethylnitrosamine (DEN) plus CCl 4 (DEN-CCl 4 ) model of HCC 13 . Consistent with previous studies [71] [72] [73] , treatment with nonabsorbable antibiotics resulted in a strong reduction of fibrosis despite increased liver injury 13 . However, further studies are required to investigate how the intestinal microbiota affects HCC develop ment promoted by chronic inflammation, injury and fibrosis, without preceding carcinogen exposure.
How does the microbiota promote HCC?
As discussed, alterations in gut permeability and the gut microbiota are highly characteristic not only of late stages of all types of CLD, but also occur early in several types of CLD. Thus, the gut microbiota contributes to dis ease progression at various stages and might promote the develop ment of HCC throughout all these stages. Here, we will discuss mechanisms through which the gutliver axis promotes HCC development and progression, focusing on the role of the leaky gut and dysbiosis (FIG. 1) .
HCC promotion via a leaky gut and the MAMP-TLR axis. High circulating LPS levels in mice and patients with CLD as well as in HCC 14, 24, 77, 78 demonstrate the pres ence of a leaky gut during multiple stages of CLD and hepatocarcinogenesis (FIG. 1 Figure 1 | Contribution of the gut microbiota to hepatocarcinogenesis: mechanisms and therapeutic targets. Dysbiosis and the leaky gut promote the progression of liver disease and the development of hepatocellular carcinoma (HCC) via multiple mechanisms, including the release of cancer-promoting and senescence-promoting metabolites such as deoxycholic acid (DCA) from the dysbiotic microbiota, and increased hepatic exposure to gut-derived microbiota-associated molecular patterns (MAMPs) such as lipopolysaccharide (LPS), which in turn promote hepatic inflammation, fibrosis, proliferation and the activation of anti-apoptotic signals. These cancer-promoting signalling pathways can be interrupted at several levels: using probiotics to restore eubiosis; using antibiotics to eliminate disease-promoting bacteria and decrease the release of MAMPs and metabolites from the leaky gut; using agents to improve the gut barrier; and potentially using inhibitors of bacterial metabolism to reduce the production of cancer-promoting metabolites by the gut microbiota. FXR, farnesoid X receptor; HSC, hepatic stellate cell; TLR, Toll-like receptor; SASP, senescence-associated secretory phenotype.
induced by DEN-CCl 4 was attenuated in gut sterilized and germfree mice compared with their specific pathogenfree counterparts 13 . In addition to causing character istic infectious complications in endstage liver disease, increased bacterial translocation also generates a chronic inflammatory state in the liver. The inflamma tory responses in the liver are mediated by interaction between MAMPs and host PRRs, specifically the TLRs 79 . Accordingly, chronic infusion of lowdose LPS via osmotic pumps promotes HCC development in mice 13 . Likewise, disruption of the gut barrier by administration of dextran sulfate sodium not only results in increased systemic LPS levels and increased liver fibrosis, but also promotes HCC formation in mice 80, 81 . Conversely, inhib ition of TLR4 signalling suppresses liver inflammation, fibrosis and HCC formation in mice and rats 13, 14, 73 . 13 . LPS from the leaky gut seems to promote hepatocarcinogenesis via multiple cellular targets, including HSCs, the hepatocyte-tumour compartment and Kupffer cells. In HSCs, TLR4 activ ation leads to an NFκBmediated upregulation of the hepatomitogen epiregulin 13 . Epiregulin is an epidermal growth factor family member with a potent mitogenic effect on hepatocytes 82 . Accordingly, epiregulin deficient mice displayed reduced hepatocarcinogenesis when treated with DEN-CCl 4 (REF. 13 ). Another key mechanism by which the LPS-TLR4 axis promotes HCC formation is via NFκBmediated prevention of hepatocyte apoptosis. Accordingly, expression of the apoptosis marker cleaved caspase 3 in TLR4deficient and gutsterilized mice is inversely correlated with the formation of tumours 13 . However, due to the lack of studies in mice with con ditional TLR4 ablation, it remains unclear whether this survival pathway is directly activ ated in the hepatocytetumour cell compartment, or whether it might involve paracrine signals from neighbouring TLR4expressing cells such as HSCs or Kupffer cells. Moreover, it has been demonstrated that activation of the LPS-TLR4 signal ling pathway in Kupffer cells leads to TNFdependent and IL6dependent compensatory hepatocyte prolifer ation as well as reduced oxidative stress and apopto sis 14 . In addition, TLR4 activation in HCC cell lines by LPS enhances their invasive potential and induces the epithelial-mesenchymal transition 83 . To delineate the contrib ution of TLR4 on specific cell types in the liver, further experiments in mice with conditional TLR4 ablation are required.
Together, these data clearly show that the leaky gut, via MAMP-TLRmediated signals, contributes to hepato carcinogenesis. Dysbiosis (discussed later) and the leaky gut are probably intimately linked; it is likely that intestinal dysbiosis contributes to a leaky gut by multi ple mechanisms, such as dysbiosisinduced alter ations of the intestinal barrier as well as a shift to bacterial species with increased propensity to translocate.
HCC promotion via dysbiosis, bacterial metabolites and immunosuppression. Increasing evidence supports a key role for dysbiosis in the development of CLD and HCC (FIG. 1) . Metagenomic studies have revealed substantial alterations in the composition of the gut microbiota in a range of CLDs as well as in patients with cirrhosis 12, 32 . The gut microbiomes of patients with advanced liver disease and cirrhosis are characterized by an increase in poten tially pathogenic bacteria, along with reduced numbers of bacteria with beneficial properties 32, 84, 85 . Studies con ducted so far on the gut microbiota in liver cirrhosis have pooled patients with different underlying liver diseases 32 , indicating that at least some of the microbial alterations in cirrhosis are common to different aetiologies, and suggesting that alterations are driven by characteristic features of endstage liver disease, such as reduced bile output and changes to the intestinal secretion of anti microbial peptides and IgA. Key changes in the com position of the intestinal microbiota in cirrhosis include enrichment of Veillonella or Streptococcus spp. as well as decreased bacteria from the order Clostridiales 32 . Of note, the majority of the patientenriched species were of buccal origin, suggesting an invasion of the gut from the mouth in liver cirrhosis 32 . The finding that the intestinal microbiota of patients with compensated cirrhosis differs from that of patients with decompensated cirrhosis 34 sug gests that cirrhosis stage, rather than the underlying liver disease, drives gut microbiota changes. However, a small scale study published in 2016 described differences in the gut microbiota between different types of underlying liver disease 86 . Thus, sufficiently powered studies in large cohorts are needed determine disease specific alterations of the gut microbiota in liver cirrhosis. In addition to alter ations in bacterial composition, evidence demonstrates bacterial overgrowth in the upper gastro intestinal tract, which in turn is associated with increased circulating LPS levels 87 . Bacterial trans location in the upper gastro intestinal tract is relevant for the develop ment of liver disease owing to the anatomic connection of the small intestine to the liver. In the past few years, studies have demonstrated differences in the duodenal and salivary microbiota between healthy individ uals and patients with cirrhosis 86, 88 , suggesting that there are also quali tative and quantitative changes in the upper gastro intestinal tract that might be linked to changes in the more distal microbiota and contribute to the pathophysiology of CLD as well as the development of HCC.
Functional studies utilizing cohousing and faecal transplantation have provided evidence that dysbiosis is a transmissible driver of liver disease development and pro gression 65, 89 . In one study, HFD feeding in mice resulted in dysbiosis, with increased abundance of Gramnegative bacteria and a reduced ratio of Bacteroidetes to Firmi cutes. Transplantation of these 'dysbiotic' micro biota into controldietfed mice that had undergone bile duct ligation increased liver damage and fibrosis in the recipi ents 89 . Similarly, dysbiosis represented a trans missible risk factor in a genetic NASH model in which NASH was triggered by inflammasome deficiency; cohousing of dysbiotic inflammasome deficient mice with control mice resulted in the development of NASH in control mice 65 . Although studies demonstrating a transmissible HCC risk by transferring microbiota are still missing, several functional studies point towards a contribution of dysbiosis. As such, perturbation of the gut eubiosis by penicillin increased HCC formation in rats 77 , which could be suppressed by probiotics 77 . Evidence suggests that the effects of dysbiosis on the development of liver disease and HCC are mediated by bacterial metabolites, possibly in a disease specific manner. In a mouse model of NASHinduced HCC, trig gered by the combination of DMBA and HFD (DMBA-HFD), there was a strong increase in Grampositive bacterial strains, in particular of specific Clostridium clus ters 15 . At the same time, this treatment led to increased serum levels of deoxycholic acid (DCA), a secondary bile acid whose production depends on 7α dehydroxylation of primary bile acids by the bacterial micro biota, notably Clostridium clusters. The key role of DCA in hepato carcinogenesis was further demonstrated in experiments that showed increased HCC development in mice after supplementing diets with DCA, and decreased HCC formation after inhibition of 7α dehydroxylation 15 . In concert with the TLR2 agonist lipoteichoic acid, DCA promoted a senescenceassociated secretory phenotype in HSCs, which in turn suppressed antitumour immu nity through a prostaglandinE2dependent mechanism 90 . Together, these studies link bacterial dysbiosis to altered immune responses via bacterial metabolites and MAMPs. Further studies are required to determine whether the procarcinogenic effects of dysbiotic microbiota are medi ated by additional pathways. The gut microbiota has a key role in a number of other metabolic pathways, including overall energy extraction from the diet and the generation of a wide range of important metabolites with beneficial effects for the host 91 . One example is the prod uction of shortchain fatty acids (SCFAs), which are a primary energy source for intestinal epithelial cells 91 , and might provide a link between dysbiosis and alterations of the intestinal barrier that lead to a leaky gut and increased risk of HCC development, as discussed earlier.
Targeting microbiota to prevent HCC Currently, there are no therapeutic options for HCC prevention besides treating the underlying disease. On the basis of its important contribution to CLD pro gression and hepatocarcinogenesis in particular, the gut microbiota-liver axis represents a promising target for preventive approaches (FIG. 1) . With a complete lack of clinical studies testing this strategy, targeting the gut microbiota-liver axis represents an exciting and under studied clinical opportunity, supported by a large number of studies preclinical studies showing a drastic (~80%) reduction of HCC development in mouse and rat models [13] [14] [15] . Moreover, several smallscale clinical studies have suggested that antibiotics such as norfloxacin and rifaximin increase survival in patients with liver cirrho sis [92] [93] [94] [95] . Targeting the gut microbiota for HCC prevention is particularly attractive as it might utilize currently FDA approved drugs with a high safety profile in patients with CLD, such as the nonabsorbable antibiotic rifaximin (used to treat hepatic encephalopathy), or other approaches with low risk of severe adverse effects, such as probiotics or faecal microbiota transplantation (FMT). Moreover, the gutmicrobiota-liver axis has a key involvement in many complications of CLD and could be targeted to 'kill several birds with one stone': in addition to poten tially reducing the risk of HCC development, targeting the gut microbiota-liver axis has been shown to reduce liver fibrosis 73, 96 and portal hypertension 97 in rodents, and spontaneous bacterial peritonitis 98 and hepatic encephalo pathy 99 in patients. As the strongest effects of antibiotics on HCC and complications of cirrhosis in mice and patients, respectively, have been observed in advanced disease stages, preventive strategies that target the gutliver axis seem most promising in patients with cirrhosis and at high risk of HCC development, which would also reduce the number of patients that would be unnecessar ily subjected to such treatments. Moreover, targeting this axis is unlikely to have a major effect on patients in which the gut-liver axis is not a dominant driver of disease pro gression, HCC development and mortality, for example those with peri natal HBV infection, high HBV titres and minimal liver fibrosis. Although there is accumulating evidence that the gut microbiota modulates responses to chemo therapy 100, 101 and immunomodulatory thera pies 102, 103 , there is currently no data supporting the con cept of targeting the gutmicrobiota-liver axis for the treatment of HCC. With increased understanding of the underlying pathophysiology, the number of clinically feasible approaches to target the gutmicrobiota-liver axis is continuously growing (TABLE 1) .
Antibiotics. Because antibiotics target several path ways through which the gut microbiota promote HCC develop ment (TABLE 1) , they could represent one of the most efficient strategies to interrupt the tumour promoting gut-liver axis in CLD. Decreasing the overall number of bacteria in the gut and eliminating bacteria that have a high ability to translocate will reduce bac terial translocation and thereby inhibit pro inflammatory signals arising from leaky gut. At the same time, selective antibiotics might also block the production of HCC promoting bacterial metabolites, such as DCA, by redu cing the number of gut bacteria responsible for their synthesis 15 . Continuous gut sterilization by a cocktail of oral anti biotics, consisting of ampicillin, neomycin, metronidazole and vancomycin, effectively reduced the number and size of HCC tumours induced by DENCCl 4 or DMBA-HFD in mice 13, 15 . Moreover, this anti biotic cocktail also reduced liver fibrosis severity 73 , which often precedes HCC and represents a risk factor for HCC development in CLD 70 . Notably, administration of anti biotics at late stages of carcinogenesis, when microscopic tumours already existed, was more efficient at reducing HCC in mice than administration at earlier stages 13 . These data support the concept that HCC prevention by antibiotic treatment could be applied even at late stages, that is, in patients with advanced cirrhosis and high risk of HCC development. However, findings from mice can not be translated directly to patients as longterm admin istration of the employed antibiotic cocktail would be deleterious due to the depletion of almost all detectable commensal microbiota (>99.5%) 73, 104 and the inclusion of nephrotoxic drugs, such as neomycin. Moreover, HCC prevention with antibiotics would require longterm, possibly lifelong administration. Thus, the use of single antibiotics with a high safety profile in patients with CLD represents the only clinically feasible approach.
Currently, two antibiotics, norfloxacin and rifaxi min, have shown beneficial effects in patients with CLD or murine HCC models and fulfil these criteria. Vancomycin, another antibiotic that has shown effec tiveness as monotherapy in the prevention of HCC in the combined DMBA-HFD mouse model 15 , is rarely used for longterm therapy in patients and might cause a number of potentially severe adverse effects. Gramnegative bac teria have been found to be the most adept at translocating to the mesenteric lymph nodes and are the most frequent cause of spontaneous bacterial infections in patients with cirrhosis [105] [106] [107] . Norfloxacin, a poorly absorbed quinolone, is currently one of the drugs of choice for the primary or secondary prophylaxis of spontaneous bacterial perito nitis and infections in highrisk patients with cirrhosis 108 . Clinical trials in patients with advanced cirrhosis have shown that longterm use of orally administered nor floxacin is safe, produces a marked reduction of Gram negative bacteria in the faecal microbiota 109 , reduces the 1year probability of developing spontaneous bacterial peritonitis and hepatorenal syndrome and improves 3month survival 92 . Although these data show that nor floxacin can effectively reduce small intestinal bacteria overgrowth and bacterial translocation in patients with advanced cirrhosis, the effects of norfloxacin on HCC development in patients with liver cirrhosis are not known. A major problem with the use of norfloxacin is the development of antibiotic resistance [110] [111] [112] , suggesting that it might be suitable for treatment lasting weeks to months but not for longterm or lifelong application in patients with cirrhosis. Rifaximin is a nonabsorbable antibiotic with broadspectrum antimicrobial activity and an excellent safety profile 113 that was initially approved for the treatment of traveller's diarrhoea but is increas ingly used for the prevention of hepatic encephalo pathy 99 . Moreover, rifaximin reduces the development of spon taneous bacterial peritonitis and seems to improve portal hypertension, suggesting that it effectively targets the gut-liver axis in advanced liver disease 93, 114, 115 . Similar to norfloxacin, rifaximin has been noted to increase sur vival in patients with advanced liver cirrhosis in several smallscale trials [92] [93] [94] [95] . Notably, rifaximin reduces HCC development in the DEN-CCl 4 model of HCC, albeit less efficiently than the quadruple antibiotics cocktail already described 13 . Despite the large number of patients receiving rifaximin for the prevention of hepatic encephalopathy, the effects of rifaximin on HCC development remain unknown. Thus, studies that determine the effects of longterm rifaximin treatment on HCC development are urgently needed. In contrast to norfloxacin, clinically relevant development of resistance to rifaximin has not been reported, suggesting that it is wellsuited for long term or even lifelong treatment. As data from mouse and rat models show that non absorbable anti biotics and norfloxacin improve ALD 48, 116 and insulin resistance in NAFLD 117 , they might be particularly attractive for HCC prevention in these patient groups.
Probiotics. Probiotics have been proposed as a means of reequilibrating the gut microbiota in CLD by restoring beneficial bacteria. Although a large number of stud ies have demonstrated the effectiveness of probiotics in treating liver diseases both in animal models and in patients (reviewed elsewhere 118, 119 ), substantial controv ersy remains on the basis of: the inability of most pro biotics to permanently colonize the gut; largely unknown mechanisms of action, in particular given the lack of permanent colonization; the large number of different combinations of bacteria within different probiotics that have not been systemically evaluated and compared for their efficacy in CLD; and in view of a lack of large scale studies, potential publication bias towards studies reporting positive results. So far, probiotics have only been investigated in murine HCC models and data in patients are lacking (TABLE 1) . In a rat model of DEN induced hepatocarcinogenesis, administration of VSL#3 (containing Streptococcus thermophiles, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus) mitigated enteric dysbiosis, ameliorated intestinal inflammation and decreased liver tumour growth and multiplicity 77 . In a subcutaneous transplant mouse model, the probiotic mixture Prohep (compris ing Lactobacillus rhamnosus GG, Escherichia coli Nissle 1917 and heatinactivated VSL#3) reduced tumour size and weight 120 . The authors suggested that a shift of the gut microbiota composition towards beneficial bac teria such as Prevotella and Oscillibacter, and produc tion of anti inflammatory mediators by these bacteria, decreased levels of type 17 T helper cells within tumours and thereby limited tumour growth. However, the effects of pro biotics on endogenously arising tumours are not known. To date, there are several clinical trials under way testing pro biotics in patients with CLD but none in patients with HCC. A doubleblind trial showed that daily intake of VSL#3 reduced the risk of hospitalization for hepatic encephalopathy, as well as CTP score and model for endstage liver disease (MELD) scores, in patients with cirrho sis 121 . Another randomized trial showed that 4month supplementation with VSL#3 improves NAFLD severity in children 122 . The possible mechanisms of action include modulation of the host microbiota 123 , improve ment of gut barrier function and modulation of the immune system. However, further studies are required to confirm these data, extend human studies and investigate mechanisms of action.
FMT. FMT has successfully been used in patients with C. difficile infection, resulting in restoration of eubiosis and clinical improvements that were superior to stand ard antibiotic therapy 18 . Currently, FMT is being evalu ated in clinical trials for a number of additional diseases including NASH 124 and cirrhosis
125
. A randomized con trolled trial demonstrated amelioration of hepatic and peripheral insulin resistance in patients with metabolic syndrome who had received faecal microbiota from lean donors 126 . However, one needs to keep in mind that patients receiving FMT for recurrent C. difficile infection have usually undergone multiple courses of antibiotic treatment, and present with markedly reduced micro bial diversity 18 . Thus, these patients not only represent an ideal 'breeding ground' for transplanted microbiota but also have a disease that is clearly linked to reduced bacterial diversity and overgrowth of single and measur able patho genic strains. Nonetheless, it is conceivable that FMT might also restore eubiosis in patients with CLD, similar to effect seen in the trial of Vrieze et al. 126 , and that FMT might reduce or delay the development of HCC (TABLE 1) . However, no data currently support this premise and a number of hurdles must be overcome. Most importantly, it is unclear whether the severe alter ations of the gastro intestinal ecology in cirrhosis would allow permanent restoration of the microbiota by FMT; these effects might be transient and the microbiota could ultimately revert to the preFMT state. Moreover, there is substantial concern that viral infections and other pathogens might be transmitted via FMT, which would be particularly harmful to patients with advanced liver disease owing to their immuno suppression. In the future, faeces might be substituted in favour of defined mixtures of cultured bacteria that resemble the human micro biota transplanted via FMT and confer the same beneficial effects. This approach will not only alleviate concerns regarding the inadvertent transmission of disease causing pathogens through FMT, but also make intestinal microbiota therapy more acceptable to patients and physi cians 127 . Once this goal has been achieved, patients with advanced liver disease should be consid ered as potential candidates to study effects on disease progression and HCC development.
TLR antagonists.
Several studies have shown a key role for the TLR4 pathway as a mediator of the disease promoting effects of the gut-liver axis in CLD and hepato carcinogenesis 13, 14, 73 . On the basis of these find ings, blocking the TLR4 pathway might represent another aven ue for HCC prevention (TABLE 1) . With detailed knowledge about mechanisms by which LPS activates TLR4, a variety of TLR4 antagonists have been developed, which can be clustered into several groups: compounds binding and sequestering LPS, such as poly myxin B; compounds antagonizing LBP and CD14-LPS interactions 128 ; compounds targeting LPS-MD2 (MD2 is also known as Ly96) or LPS-MD2-TLR4 interactions, such as E5531 and eritoran (E5564); compounds directly targeting TLR4, such as resatorvid (TAK242); and molecules inhibiting TLR4 activity such as thalidomide (reviewed elsewhere 129 ). Eritoran 130 and resatorvid 131 improved survival in animal models of sepsis, but did not reduce mortality in patients with severe sepsis 132, 133 . So far, none of these agents have been tested in clin ical trials in patients with CLD or HCC. Although TLR antagonists represent an exciting opportunity, longterm inhibition of TLR4 could result in immunosuppression, which might be deleterious due to the severely immuno compromised state of patients with CLD. Thus, the safety profile of TLR4 antagonists needs to be carefully evalu ated before longterm studies for prevention of HCC and other complications of CLD can be considered.
Targeting the gut barrier. On the basis that the leaky gut is a major driver of liver disease progression and HCC development (FIG. 1) , targeting the gut barrier seems an attractive therapeutic approach (TABLE 1) that might avoid some of the complications of targeting the microbiota (such as development of resistance and/or decreased microbial diversity) or receptors that mediate the disease promoting effects of a leaky gut (such as immuno suppression resulting from TLR4 antagonism). Moreover, therapies that target the gut barrier could potentially be combined with other approaches that directly target the gut microbiota or liver. With improved understanding of the gut barrier and mech anisms that disrupt the gut barrier in cirrhosis, targeting the gut barrier via specific pharmacological approaches seems to be realistic.
Bile acids are an important regulator of the gut barrier. Decreased bile secretion in rodents by either ligation of the common bile duct or induction of cirrho sis contributes to bacterial translocation, which is not only caused by intestinal bacterial overgrowth but also by increased gut permeability 20, 28, 134 . Notably, these effects are attenuated after oral administration of bile acids in different experimental cirrhotic models 20, 134, 135 . FXR is a receptor for bile acids that mediates their effects on the intestinal epithelial barrier as well as multiple effects on the liver, such as suppression of bile acid syn thesis, inhib ition of liver inflammation, promotion of liver regeneration and tumour suppression (reviewed elsewhere 136 ). Many of the hepatic effects of FXR activ ation are mediated by intestinal FXR receptors, resulting in the release of FGF19, which then acts on targets in the liver [136] [137] [138] [139] . Fxrdeficient mice exhibit compromised intestinal integrity, with further deterioration after bile duct ligation 20 , and a high incidence of HCC 140 . Accordingly, FXR activ ation by agonists GW4064 or obeticholic acid (OCA) attenuates mucosal injury, ileal barrier perme ability, bacterial overgrowth and bacterial translocation in mice and rats 20, 21, 141, 142 . Moreover, OCA improves portal hypertension (which might contribute to bacterial translocation in cirrhosis) in rats treated with thioacetamide or bile duct ligation 143 . OCA has a high safety profile in patients with NASH as demon strated in the FLINT trial, with the major adverse effects being pruritus and alterations of serum lipid profiles 144 . Thus, OCA seems to be a promising candidate for HCC prevention thera pies, and could be particularly effective by correcting multi ple abnormalities in the gut-liver axis that promote the development of chronic inflammation and HCC in patients with cirrhosis.
Increased production of TNF by monocytes in mesen teric lymph nodes constitutes one of the main factors increasing tight junction permeability 145, 146 . TNF increases tight junction permeability by decreasing expression of tight junction proteins as well as by activ ating myosin light chain kinase (MLCK) 147 . Treatment with an antiTNF monoclonal antibody decreases the incidence of bacterial translocation in experimental cirrho sis in rats 148 . However, translating these findings to patients might be difficult because of strong immuno suppressive effects of TNF inhibitors and increased rates of severe infection. Owing to these adverse effects, long term antiTNF therapy in patients with CLD might con fer more harm than benefit, and further efforts need to be made to develop therapies that act locally to improve gut barrier function without negatively affecting systemic immune responses.
Prokinetics. Another factor that contributes to intestinal bacteria overgrowth in liver cirrhosis is gut dysmotil ity 149 . The prokinetic drug cisapride not only decreases intestinal transit time but also inhibits intestinal bacterial overgrowth and bacterial translocation, both in animal models 150, 151 and in patients with cirrhosis 150, 152 . However, the longterm benefits of prokinetics such as cisapride have yet to be determined in patients with CLD (TABLE 1) . One of the purported mechanisms for altered motility in cirrho sis is increased adrenergic activity. Accordingly, non selective βadrenergic blockers decrease intestinal transit time and reduce intestinal bacterial overgrowth, intestinal permeability and bacterial translocation in experimental models of cirrhosis and in patients [153] [154] [155] [156] [157] . Interestingly, a retrospective longterm observational study suggests that propranolol treatment might decrease HCC occur rence in patients with HCVrelated cirrhosis 158 , indicating a potential role for HCC prevention.
Malnutrition is common in patients with CLD and is associated with increased morbidity and mortality 149 . Of note, malnutrition increases intestinal permeability and facilitates bacterial translocation 159 . Nutritional sup port, therefore, represents an important aspect to correct dysbiosis in patients with CLD.
Clinical translation
Current data from mouse models suggest that targeting the gut-liver axis has a potential role for the primary or secondary prevention of HCC, but not for the treatment of HCC (TABLE 2) . Primary prevention seems the most appealing approach, and could be tested prospectively in large cohorts of patients with liver cirrhosis and at high risk of HCC development. Alternatively, the efficacy of primary prevention could be evaluated retrospectively in cohorts of patients who have already received treat ment, for example rifaximin for the prevention of hepatic encephalopathy. Primary prevention most likely requires longterm if not lifelong treatment. As discussed in the previous sections, good safety and beneficial effects on nonHCC complications of CLD are the most important selection criteria for the bestsuited drug candidates. In this regard, rifaximin is probably the candidate with the best safety profile, and there is strong evidence that it positively affects additional complications of CLD such as hepatic encephalopathy, portal hypertension and liver fibrosis, and possibly even improves overall survival. The efficacy of targeting the gut-liver axis for secondary pre vention could be tested in patients who have undergone curative HCC resection. Although this strategy would require a welldefined cohort of patients with high risk for HCC relapse, one would still have to carefully dis tinguish between tumour recurrence and de novo tumour formation, as therapies such as rifaximin might positively affect one but not the other.
Conclusions
Overwhelming evidence from the past three decades sup port a key contribution of the gut microbiota to multiple aspects of liver disease progression, thereby contributing to a hepatic environment that promotes development and progression of HCC. The mech anisms by which the gut microbiota promotes the development of liver disease and HCC include dysbiosis, which results in altered bac terial metabolites such as the cancer promoting second ary bile acid DCA, as well as a leaky gut, which promotes chronic hepatic inflammation via TLRmediated signals. Currently, it is not clear whether chronic inflammation driven by the trans location of MAMPs from the leaky gut is the domin ant contributor to hepatocarcino genesis, whether alterations of bac terial metabolites are restricted to specific diseases such as NAFLD, or whether both mechanisms work synergistically to promote the development of HCC in most settings. Some alterations of the gut micro biota are probably diseasespecific, and therefore some mechanisms by which the gut micro biota promotes the progression of liver disease and HCC could be -at least in part -diseasespecific. Hence, better understanding of diseasespecific alterations and thorough determination of their functional contrib utions to liver disease development are needed. Detailed know ledge about key pathways through which the gut micro biota affect CLD and HCC development could enable the development of broad or tailored therapeutic approaches that block the diseasepromoting gut-liver signalling axis. Moreover, our current understanding of the contrib ution of the gut microbiota is largely based on animal models and faecal microbiota samples from patients. As many of the key changes in the gut-liver axis occur in the small intestine and possibly also within mucosa adherent microbiota, better analysis of the human micro biome at different anatomic sites is needed. Finally, many types of CLD that confer a high risk of HCC develop ment cannot be adequately modelled in mice. Thus, more effort should be put into translating our current know ledge on the HCCpromoting role of the gut-liver axis into welldesigned trials in patients.
